China Medical Tourism Pathways: Comparing Boao, Beijing, Shanghai and Guangzhou
- MedBridgeNZ
- Jul 13
- 8 min read
This guide outlines administrative pathways for international patients considering medical tourism in China. MedBridgeNZ coordinates logistics, document formatting, and administrative liaison; all clinical, diagnostic, and eligibility decisions remain strictly with the receiving medical institutions.
Quick Answer
China’s cross-border medical landscape can be understood as two broad tracks: (1) the Boao Lecheng special-access regulatory pathway; and (2) institution-led tertiary-care pathways in Beijing, Shanghai, and Guangzhou. Within the second track, each city has different specialist resources and administrative requirements.
Boao Lecheng offers a regulated special-access pathway for certain eligible imported drugs and devices.
Beijing has national referral institutions often considered for rare diseases and complex surgery.
Shanghai has established hematology and CAR-T evaluation resources.
Guangzhou has specialist services in solid-tumor oncology and proton radiotherapy.
The appropriate route depends entirely on the diagnosis, prior treatment history, institutional eligibility criteria, and current regulatory availability.
China Medical Tourism Pathways: Comparative Decision Framework
Pathway | May Be Relevant For | Who Decides Eligibility | Main Administrative Questions |
Boao Lecheng | Certain special-access drugs/devices, such as premium intraocular lenses (IOLs). | Designated institution and regulatory authorities. | Product availability, regulatory approval, monitoring requirements. |
Beijing | Rare disease diagnostic review, complex cardiovascular or neurosurgery. | Receiving hospital/specialist. | Record completeness, appointment pathway, language barriers. |
Shanghai | Hematological malignancies, CAR-T evaluation, high-resolution diagnostic imaging. | Cellular-therapy center/multidisciplinary team (MDT). | Product indication, organ function metrics, stay duration logistics. |
Guangzhou | Complex solid-tumor oncology, multidisciplinary reviews, proton radiotherapy. | Oncology institution. | Pathology format, imaging files, treatment plan, estimated schedule. |
How the Four Pathways Differ for International Patients
Boao Lecheng: Special Access and Regulatory Evaluation
The Boao Lecheng International Medical Tourism Pilot Zone in Hainan addresses the global "drug lag". Designated institutions in Boao Lecheng may apply for the special use of certain drugs or medical devices that have been approved overseas but are not yet registered in mainland China. Availability is product-specific and depends entirely on clinical assessment, institutional eligibility, and provincial regulatory approval.
Furthermore, certain eligible medicines may be dispensed for use outside the pilot zone under applicable controls. The medicine type, quantity, monitoring requirements, and patient eligibility are determined under the current policy and the specific clinical protocol.
Beijing: High-Volume Complex Surgical Centers
In complex surgical fields, institutional volume is often associated with specific clinical capabilities. Beijing serves as a national referral hub. Institutions such as Peking Union Medical College Hospital (PUMCH) focus on rare diseases and undiagnosed multi-system conditions, while centers like Fuwai Hospital conduct high reported procedure volumes for cardiovascular interventions.
Reported Institutional Figure
Published Source: Fuwai Hospital Clinical Operations Data
Reporting Period: 10-year tracking period up to 2023
Reported Measure: The 30-day mortality rate for isolated coronary artery bypass grafting (CABG) was maintained below 0.5% [11].
Important Limitation: Institutional figures reflect overall volume metrics and may not predict outcomes for an individual patient.
Shanghai: Hematology and Cellular Therapy Pathways
Shanghai represents an established center for commercialized advanced therapies and extensive international medical services. Centers like Ruijin Hospital act as major hubs for hematological treatments and the commercial application of CAR-T cell therapies.
Indicative Published Cost Estimate
Facility/Pathway: Commercial CAR-T Therapy Pathways (Shanghai/China)
Reported Estimate: The source report cites indicative estimates of approximately USD 150,000–230,000 for some commercial CAR-T pathways in China [12].
Important Limitation: Actual costs can vary substantially by product, hospital, eligibility, length of stay, supportive care, and complications. These figures are not quotations or guarantees.
Guangzhou: Advanced Oncology and Radiotherapy
Guangzhou's specialized medical infrastructure focuses heavily on comprehensive oncology. The Sun Yat-sen University Cancer Center (SYSUCC) has specialist programs in the management of gastrointestinal and respiratory malignancies, while facilities like the Guangzhou Concord Cancer Center provide access to advanced proton beam radiation therapy.
Indicative Published Cost Estimate
Facility/Pathway: Proton Beam Radiation Therapy (Guangzhou Concord Cancer Center)
Reported Estimate: A complete course of proton beam radiation therapy is estimated between USD 41,800 and 55,000.
Important Limitation: Cost figures are indicative published estimates only. They may exclude preliminary evaluation, additional imaging, pathology review, complications, accommodation, travel, and post-treatment follow-up.
Not Sure Where to Begin Administratively?
Before contacting a hospital, international patients can request an administrative completeness check of their available records. Based on the documents provided and available institutional intake requirements, MedBridgeNZ can flag apparent documentation gaps, potential translation needs, and file-format issues before submission.
Free initial administrative intake review. This is not a medical assessment, treatment recommendation, or eligibility decision. Hospital acceptance, treatment availability, costs, and visa outcomes are not guaranteed.
Administrative Friction: Records, Financial Logistics, and Visas
The public healthcare infrastructure in China is engineered to process domestic patient volumes utilizing highly digitized, real-name registration systems. For an international patient, this creates specific administrative friction points.
DICOM Imaging and Medical Records: Some institutions may request complete, viewable DICOM image sets together with translated radiology reports, clinical summaries, pathology reports, and prior treatment records. Raw DICOM images generally are not translated. File naming, upload procedures, and language requirements vary by institution, and the receiving hospital determines whether translations or additional documentation are required.
Financial Logistics: Payment methods vary by institution. Some hospitals may require bank transfer or an institution-specific deposit process for larger amounts. MedBridgeNZ can coordinate administrative communication about payment instructions but does not guarantee credit card acceptance or international commercial insurance reimbursement. Treatment fees are payable strictly according to the receiving institution’s arrangements.
Visa and Entry Coordination: Entry requirements vary by nationality, travel purpose, intended length of stay, and current immigration policy. Patients should not assume that general visa-free entry applies to planned medical treatment. Before booking travel, they should confirm the permitted entry purpose and required documents with the relevant Chinese embassy, consulate, or immigration authority. For a broader overview of how patients generally navigate these requirements, read our comprehensive China medical tourism visa guide. Where requested, MedBridgeNZ can help organize hospital-issued supporting documents, but does not provide immigration advice, issue visas, select visa categories, or guarantee approval.
Factors That May Delay or Prevent Institutional Review
A receiving institution may decline, defer, or request additional information for a case. Relevant factors can include:
Medical stability for travel.
Incomplete medical records, missing pathology slides, or unsupported imaging formats.
The need for emergency-level care or active ICU life support during transit.
Lack of an appropriate receiving service or clinical trial opening.
Inability to meet the institution’s administrative or financial documentation requirements.
Clinical and travel suitability must be assessed by qualified treating professionals prior to cross-border transit.
Representative Administrative Pathway
The following pathway is illustrative and does not describe a specific MedBridgeNZ patient.
Clinical Context: An international patient requires multidisciplinary review for an advanced solid tumor.
Records Prepared for Review: The patient submits medical histories and imaging files. The accompanying reports are formatted and translated into standard Chinese clinical terminology to meet institutional intake parameters.
Institutional Review Channel: The formatted dossier is routed to an oncology center for remote feasibility assessment by the designated medical team.
Institutional Feedback: The institutional experts may outline the necessity for supplementary molecular subtyping or determine if the patient qualifies for their specific protocols.
Administrative Next Steps: If the receiving institution agrees to proceed and issues any required supporting or invitation documents, MedBridgeNZ can help organize the administrative next steps, including document compilation, clarification of hospital payment instructions, and agreed bilingual on-the-ground support.
Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression.
What MedBridgeNZ Coordinates
Connecting with specialist hospitals and international departments requires strict adherence to institutional protocols. MedBridgeNZ coordinates this complex journey through a structured logistical framework. Learn more about our comprehensive international medical concierge services, which include:
Initial Administrative Review: Patients submit available medical records, pathology reports, and imaging files. MedBridgeNZ organizes the materials and identifies potential formatting or translation gaps before institutional submission.
Hospital and Specialist Liaison: Based on the information provided, MedBridgeNZ coordinates inquiries with potentially relevant hospitals or specialists. The receiving institution determines whether it can review or accept the case.
Travel and On-the-Ground Coordination: Where treatment in China is being considered, MedBridgeNZ can coordinate agreed non-clinical arrangements such as appointment logistics, bilingual accompaniment, local transport, and accommodation.
Prepare Your Records for Institutional Review
Submit your available diagnosis summary, treatment history, pathology reports, and imaging information. Our team will explain the administrative intake process and identify any obvious documentation gaps.
Free initial administrative intake review. This is not a medical assessment, treatment recommendation, or eligibility decision.
Frequently Asked Questions
How do Boao, Beijing, Shanghai and Guangzhou differ?
Boao Lecheng offers a regulated special-access pathway for certain eligible imported drugs and devices. Beijing has national referral institutions for rare diseases and complex surgery. Shanghai has established hematology and CAR-T evaluation resources. Guangzhou has specialist services in solid-tumor oncology and proton radiotherapy. The relevant institution determines whether any pathway is suitable or available.
Who determines whether a patient is eligible?
Clinical eligibility is determined by the receiving clinical team and institution and, where applicable, the relevant ethics committee or regulatory authority.
What records are usually needed for remote review?
Requirements vary by institution. Commonly requested materials include a diagnosis summary, treatment history, pathology reports, operative notes, and relevant imaging. The receiving hospital determines whether Chinese translations, pathology slides, or additional documents are required.
Do DICOM images need to be translated?
No. Raw DICOM image data are not translated. A hospital may request translated accompanying radiology reports, an organized image index, or specific upload arrangements, depending on its intake process.
Can MedBridgeNZ recommend a treatment?
No. MedBridgeNZ acts strictly as an administrative and logistics coordinator. We do not provide medical advice, diagnosis, treatment recommendations, or clinical eligibility decisions.
How are treatment costs estimated?
Treatment costs vary widely based on the specific hospital, the required procedures, the length of stay, and potential clinical complications. MedBridgeNZ assists patients in understanding the hospital's official payment instructions and estimated deposit requirements.
What entry permission or visa may be required?
Requirements vary by nationality, travel purpose, intended length of stay, and current policy. Patients should confirm directly with the relevant Chinese embassy, consulate, or immigration authority whether visa-free entry is permitted for the planned journey or whether a visa is required. MedBridgeNZ cannot determine visa eligibility or guarantee approval.
What does MedBridgeNZ coordinate?
We coordinate the translation of medical records, facilitate administrative communication with hospital international departments, assist in compiling necessary logistical documentation, and manage on-the-ground arrangements such as bilingual accompaniment and local transport.
References
Conditions for Visa-Free Entry to China — https://auckland.china-consulate.gov.cn/eng/lsqz/gg/202605/t20260519_11912956.htm
Hainan Emerges as China’s Premier International Medical Tourism Destination — https://english.www.gov.cn/news/202507/05/content_WS6868ce92c6d0868f4e8f3dc5.html
Boao Lecheng Special Access Medical Pathways: A Guide for International Patients — https://www.medbridgenz.com/post/boao-lecheng-special-access-medical-pathways
Beijing Hospitals Top Annual Comprehensive Rankings of Chinese Hospitals — https://english.beijing.gov.cn/latest/news/202211/t20221130_2869085.html
Fuwai Hospital: World-Leading Cardiovascular Center in China — https://www.medbridgenz.com/hospital-info/fuwai-hospital
Ruijin Hospital Shanghai: International Appointments & VIP Guide — https://www.medbridgenz.com/ruijin-hospital
CAR-T Therapy in China: Costs, Hospitals & 2026 Patient Guide — https://www.medbridgenz.com/post/car-t-therapy-china-cost-guide-2026
Medical Oncology — Sun Yat-sen University Cancer Center — https://english.sysucc.org.cn/index_64.aspx?lcid=99
Radiation Oncology — Sun Yat-sen University Cancer Center — https://english.sysucc.org.cn/index_64.aspx?lcid=98
Proton Therapy and Cancer Treatment FAQs — Guangzhou Concord Cancer Center — https://www.concord-hospital.org/faqs
Report on cardiovascular health and diseases in China 2021: an updated summary — https://pmc.ncbi.nlm.nih.gov/articles/PMC10320777/
Gilead's Kite Pharma Exits China Market as Fosun Fully Acquires Joint Venture Fosun Kite — https://www.vcbeathealth.com/article/14258
Published by: MedBridgeNZ Patient Coordination Team
Last reviewed: July 13, 2026
Scope: Administrative and logistics information for international patients
Disclaimer: MedBridgeNZ is an international medical concierge and logistics coordination service. We do not provide medical advice, diagnosis, treatment, prescriptions, or clinical eligibility decisions. All clinical decisions are made by appropriately qualified healthcare professionals and receiving institutions. Treatment availability, hospital acceptance, costs, timelines, visa requirements, and regulatory pathways may change and are not guaranteed. Cost figures are indicative only and do not constitute quotations. Always consult your treating physician before making decisions about international medical travel.
References to hospitals, physicians, or treatment pathways are for informational purposes and do not imply endorsement, partnership, or guaranteed access unless expressly stated.
